Management of Immune Checkpoint Inhibitor Toxicities
| Autor: | Félix Lefort, Baptiste Sionneau, Charlotte Domblides, Quentin Durrechou, Amandine Quivy, Marine Gross-Goupil, Alain Ravaud, Amaury Daste |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Programmed cell death business.industry Immune checkpoint inhibitors Ligand (biochemistry) 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Toxicity Cancer research Cytotoxic T cell Endocrine system Medicine Cytotoxicity business Adverse effect |
| Zdroj: | Cancer Management and Research. 12:9139-9158 |
| ISSN: | 1179-1322 |
| DOI: | 10.2147/cmar.s218756 |
| Popis: | Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death protein 1) or PDL-1 (programmed cell death ligand protein 1) represent ICIs that can be used as monotherapy or in combination with other agents. The toxicity p\rofiles of ICIs differ from the side effects of cytotoxic agents and come with new toxicities like immune-related adverse events. Typically, these toxicities occur in all organs. However, the main organs affected are the skin, digestive, hepatic, lungs, rheumatologic, and endocrine. Most of the immune toxicity that occurs is low grade but some more severe toxicities can occur that require a rapid diagnosis and appropriate treatment. The recognition of symptoms by physicians and patient is necessary to resolve them rapidly and adapt treatment to allow the toxicity to resolve. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|